Jazz Pharmaceuticals, Inc.
JAZZStock
$242.18+113.11%52W
Market Cap$15.24B
P/E19.93x
Div yield—
Beta0.37
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)31.84%
Price vs S&P 500 (4W)4.89%
VGM Score55.33
Market Capitalization$15.24B
P/E Ratio (Annual)19.93x
Earnings Surprise History
Q1 266.34est. 4.66
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.26
4.25
4.24
4.20
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
JAZZJazz Pharmaceuticals, Inc. | C | C | B | $242.18 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical company with approved treatments in neuroscience and oncology. Its portfolio of nine drugs includes leading franchises such as Xyrem/Xywav for narcolepsy, Epidiolex for severe epilepsy (acquired in 2021 from GW Pharmaceuticals), and oncology medications including Zepzelca, Rylaze, and Vyxeos. The company focuses on high-unmet-need therapeutic areas with limited competitive options.